mazdutide vs survodutide
updated
mazdutide (tier A) vs survodutide (tier A): what each is, why each got its grade, half-life and source counts side by side.
mazdutide · tier A
the GLP-1 + glucagon dual agonist approved in China. 14.01% weight loss in GLORY-1 phase 3 at 48 weeks, 16.65% at the higher 9 mg dose in GLORY-2. not FDA-approved.
tier rationale
mazdutide clears a high bar: a pivotal phase 3 obesity readout (GLORY-1, 14.01% at 6 mg over 48 weeks; GLORY-2, 16.65% at 9 mg over 60 weeks against 1.50% on placebo) and a 2025 NMPA approval in China for chronic weight management and type 2 diabetes. that is real efficacy with a real label behind it. it lands at A rather than S because the pivotal efficacy was generated in a single-ethnicity Chinese population and there is no US approval, only an active US phase 2 program. strong dual-agonist data, narrower geographic and regulatory reach than the FDA-approved incretins.
survodutide · tier A
Investigational GLP-1/glucagon dual agonist. In a phase 3 obesity trial, mean weight loss was 13.0% versus 5.4% with placebo at 76 weeks. Separate trials studied MASH and liver fibrosis.
tier rationale
survodutide has a published phase 3 obesity result (SYNCHRONIZE-1: about 16.6% weight loss over 76 weeks) and a phase 2 MASH signal strong enough to earn FDA Breakthrough Therapy designation. that is real, late-stage clinical evidence, which puts it firmly in A territory. it lands below retatrutide (S, deeper phase 3 weight loss) because the obesity number is more modest and it remains investigational with no approval and confirmatory MASH outcomes still years out. graded on merit: strong data, narrow no-label status.
at a glance
| mazdutide | survodutide | |
|---|---|---|
| tier | A | A |
| category | weight loss | weight loss |
| sources | 5 | 6 |
| claims evaluated | 7 | 7 |
| half-life | ~once-weekly dosing | ~6 days |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.